Description: Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
Home Page: www.aelisfarma.com
146 rue Lafaurie de Monbadon
Bordeaux,
33 000
France
Phone:
33 5 54 54 23 27
Officers
| Name | Title |
|---|---|
| Dr. Pier Vincenzo Piazza M.D., Ph.D. | CEO & Director |
| Ms. Marie Line Lefevre | Head of Finance |
| Stephanie Monlezun | Chief Operating Officer |
| Ms. Lea Floquet | Head of Legal |
| Mr. Arsene Guekam | Chief Corporate Development Officer |
| Ms. Sandy Fabre | Head of Discovery & IP Leader |
| Ms. Aurelie Boucard | Head of Preclinical Development |
| Ms. Helle Mengel | Head of Clinical Development |
| Ms. Corinne Chaimbault | Head of Pharmaceutical Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.5614 |
| Price-to-Sales TTM: | 3.36 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |